AG Meierjohann

Svenja Meierjohann: Melanoma Signal Transduction


Our group works on oncogenic signaling in melanocytes and melanoma cells and the identification of factors that are required for early steps in melanoma formation. Our main focus lies on the role of the cysteine supply in melanoma biology as well as melanoma evolution under therapy pressure, with the ultimate aim of identifying essential non-redundant targets for therapeutic intervention.

Selected Publications

Meierjohann S: Crosstalk signaling in targeted melanoma therapy. Cancer Metastasis Rev. doi: 10.1007/s10555-017-9659-z. (2017) (epub ahead of print)

Leikam C, Hufnagel AL, Otto C, Murphy DJ, Mühling B, Kneitz S, Nanda I, Schmid M, Wagner TU, Haferkamp B, Bröcker EB, Schartl M, Meierjohann S: In vitro evidence for senescent multinucleated melanocytes as a source for tumor-initiating cells. Cell Death Dis 6:e1711 (2015)

Schmitt A, Schmitz W, Hufnagel A, Schartl M, Meierjohann S: Peroxiredoxin 6 triggers melanoma cell growth by increasing arachidonic acid-dependent lipid signalling. Biochem J 471:267-279 (2015)

Leikam C, Hufnagel A, Walz S, Kneitz S, Fekete A, Müller MJ, Eilers M, Schartl M, Meierjohann S: Cystathionase mediates senescence evasion in melanocytes and melanoma cells. Oncogene 33:771-782 (2014)

Haferkamp, S., Borst, A., Adam, C., Becker, T.M., Motschenbacher, S., Windhövel, S., Hufnagel, A.L., Houben, R., Meierjohann, S. (2013) Vemurafenib induces senescence features in melanoma cells. J Invest Dermatol. doi: 10.1038/jid.2013.6.